Other metabolic agents (local RU classification)
ATC code: V03AX-MEXIDOL (Ethylmethylhydroxypyridine succinate (local code))
The manufacturer claims antioxidant, antihypoxic, and membrane-stabilizing effects via lipid bilayer stabilization and activation of succinate dehydrogenase. The molecule is not mentioned in international sources, and independent mechanism-of-action studies have not been published.
Not recommended
The term 'dyscirculatory encephalopathy' is absent from international neurology and from ICD-11. Mexidol for cognitive impairment and chronic cerebral ischemia is not mentioned in or recommendations. Evidence-based management of vascular cognitive dysfunction relies on vascular risk factor control, physical activity, and cognitive training.
Not recommended
For the treatment of anxiety disorders, Mexidol is not mentioned in international clinical guidelines (, ). Evidence-based options include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine), and cognitive behavioral therapy.
Not recommended
In international guidelines for acute ischemic stroke management ( 2019, 2021), Mexidol and other 'neuroprotectors' are not mentioned. Proven acute therapies include systemic thrombolysis with tissue plasminogen activator within 4.5 hours of symptom onset and mechanical thrombectomy within 6–24 hours in selected patients.
Not recommended
Neuroprotective therapy for TIA is not used in international clinical guidelines. TIA management relies on early antiplatelet (or anticoagulant) therapy, statin therapy, modification of risk factors, and workup for an embolic source.
Contraindicated in pregnancy per manufacturer label. International sources provide no recommendations.
ethylmethylhydroxypyridine succinate is evaluated for the following indications with varying evidence strength: Transient ischemic attack (evidence tier F), Generalized anxiety disorder (evidence tier F), Cognitive impairment (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of ethylmethylhydroxypyridine succinate (≥ 1 in 100): Nausea, Dry mouth, Somnolence, Allergic reactions. See the Safety section for uncommon and serious reactions.
Contraindicated in pregnancy per manufacturer label. International sources provide no recommendations.
ethylmethylhydroxypyridine succinate is contraindicated in: Severe hepatic disease; Severe renal disease; Pregnancy; Breastfeeding; Pediatric use (per label for most formulations). Full list in the Safety section.